ଅକ୍ସିମୋରଫୋନ

<span title="International nonproprietary name (INN): <nowiki>Mr. Ibrahem/Oxymorphone</nowiki>">Mr. Ibrahem/Oxymorphone
Clinical data
Trade names	Numorphan, Numorphone, Opana, others
Other names	14-Hydroxydihydromorphinone
AHFS/Drugs.com	Monograph
MedlinePlus	a610022
License data	<abbr class="country-name" title="<nowiki>United States</nowiki>">US DailyMed: Oxymorphone;
Routes of; </nowiki>; </nowiki>administration	By mouth, intravenous, subcutaneous, intramuscular
Drug class	Opioid
Legal status
Legal status	<abbr class="country-name" title="<nowiki>Australia</nowiki>">AU: S8 (Controlled drug); <abbr class="country-name" title="<nowiki>Canada</nowiki>">CA: Schedule I; <abbr class="country-name" title="<nowiki>Germany</nowiki>">DE: Anlage II (Authorized trade only, not prescriptible); <abbr class="country-name" title="<nowiki>United Kingdom</nowiki>">UK: Class A; <abbr class="country-name" title="<nowiki>United States</nowiki>">US: Schedule II;
Pharmacokinetic data
Bioavailability	by mouth: 10%; ; Buccal: 28%; ; Sublingual: 37.5%; ; Intranasal: 43%; ; IV, IM & IT: 100%
Protein binding	10%
Metabolism	Liver (CYP3A4, glucuronidation)
Onset of action	By injection: Within 15 min
Elimination half-life</nowiki>	7–9 hours Duration of Action: 6-8 hours Orally, 4-6 hrs Parenteral.
Duration of action	Immediate release: 5 hrs; ; Extended release: 12 hrs
Excretion	Urine, feces
Identifiers
	IUPAC name 4,5α-Epoxy-3,14-dihydroxy-17-methylmorphinan-6-one;
Chemical and physical data
Formula	C17H19NO4
Molar mass	301.342 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C1[C@@H]2OC3=C(O)C=CC4=C3[C@@]2([C@]5(CC1)O)CCN(C)[C@@H]5C4;
	InChI InChI=1S/C17H19NO4/c1-18-7-6-16-13-9-2-3-10(19)14(13)22-15(16)11(20)4-5-17(16,21)12(18)8-9/h2-3,12,15,19,21H,4-8H2,1H3/t12-,15+,16+,17-/m1/s1 ; Key:UQCNKQCJZOAFTQ-ISWURRPUSA-N ;
	(verify)

ଅକ୍ସିମୋରଫୋନ, ଅନ୍ୟମାନଙ୍କ ମଧ୍ୟରେ ଏକ ବେପାର ନାମ ଓପାନା, ହେଉଛି ଏକ ଅଫିମ ସମ୍ପର୍କୀୟ ଔଷଧ (ଓପିଓଏଡ୍) ଯାହା ମଧ୍ୟମରୁ ପ୍ରବଳ ଯନ୍ତ୍ରଣାର ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ ।^[୧] ଏହା ପାଟିରେ ଏବଂ ଇଞ୍ଜେକ୍ସନଦ୍ୱାରା ଦିଆଯାଏ ।^[୧] ଇଞ୍ଜେକ୍ସନ ଦେବାର ୧୫ ମିନିଟ ମଧ୍ୟରେ ଏହାର ପ୍ରଭାବ ଆରମ୍ଭ ହୁଏ ।^[୧] ଏହି ଔଷଧର ପ୍ରଭାବ ପ୍ରାୟ ୫ ଘଣ୍ଟା ପର୍ଯ୍ୟନ୍ତ ରହିଥାଏ ଓ ବିସ୍ତାରୋତ-ବିମୋଚନ ବଟିକାର ପ୍ରଭାବ ପ୍ରାୟ ୧୨ ଘଣ୍ଟା ପର୍ଯ୍ୟନ୍ତ ରହିଥାଏ ।^[୨]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଅଇ, କୋଷ୍ଠକାଠିନ୍ୟ, ନିଦ୍ରାଳୁ ଭାବ, ଗଲୁ ଏବଂ ଦ୍ୱନ୍ଦ୍ୱ ହୋଇପାରେ ।^[୧] ଅନ୍ୟାନ୍ୟ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ନିମ୍ନ ସ୍ତରର ଶ୍ୱାସକ୍ରିୟା, ଆଡ୍ରେନାଲ୍ ଅଭାବ ଏବଂ ନିମ୍ନ ରକ୍ତଚାପ ହୋଇପାରେ ।^[୧] ଗର୍ଭାବସ୍ଥାରେ ବ୍ୟବହାର କଲେ ଶିଶୁ ନିର୍ଭରଶୀଳ ହୋଇପାରେ, ପ୍ରସବ ସମୟରେ ଶ୍ୱାସକ୍ରିୟା ସମସ୍ୟା ହୋଇପାରେ ।^[୧] ଏହାର ଅପବ୍ୟବହାର ହେବାର ଆଶଙ୍କା ଅଧିକ ।^[୧]

୧୯୧୪ ମସିହାରେ ଜର୍ମାନୀରେ ଅକ୍ସିମୋରଫୋନ ତିଆରି କରାଯାଇଥିଲା ।^[୩] ଏହା ୧୯୫୫ ମସିହାରେ ପେଟେଣ୍ଟ ହୋଇଥିଲା ଏବଂ ୧୯୫୯ରେ ଡାକ୍ତରୀ ବ୍ୟବହାର ପାଇଁ ଅନୁମୋଦିତ ହୋଇଥିଲା ^[୪] ଏହା ଏକ ଜେନେରିକ ଔଷଧ ଭାବରେ ଉପଲବ୍ଧ ।^[୧] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ୨୦୨୧ ସୁଦ୍ଧା ୫ ମିଗ୍ରା ଟାବଲେଟର ମୂଲ୍ୟ ପ୍ରାୟ ୧.୩୫ ଡଲାର ଅଟେ । ^[୫] ଅବୈଧ ବଜାରରେ ଏହି ପରିମାଣର ବଟିକା ୨୦୧୦ ମସିହାରୁ ପ୍ରାୟ ୭.୫୦ ଡଲାର ଥିଲା ।^[୬]

ଆଧାର

↑ ^୧.୦ ^୧.୧ ^୧.୨ ^୧.୩ ^୧.୪ ^୧.୫ ^୧.୬ ^୧.୭ "OxyMORphone Monograph for Professionals". Drugs.com. Archived from the original on 4 March 2021. Retrieved 10 November 2021.
↑ Sloan P (August 2008). "Review of oral oxymorphone in the management of pain". Therapeutics and Clinical Risk Management. 4 (4): 777–87. doi:10.2147/tcrm.s1784. PMC 2621383. PMID 19209260.{{cite journal}}: CS1 maint: unflagged free DOI (link)
↑ Sinatra, Raymond S.; Jahr, Jonathan S.; Watkins-Pitchford, J. Michael (14 October 2010). The Essence of Analgesia and Analgesics (in ଇଂରାଜୀ). Cambridge University Press. p. 123. ISBN 978-1-139-49198-3. Archived from the original on 10 November 2021. Retrieved 10 November 2021.
↑ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery (in ଇଂରାଜୀ). John Wiley & Sons. p. 52X. ISBN 9783527607495. Archived from the original on 2021-10-25. Retrieved 2021-10-21.
↑ "Oxymorphone Prices, Coupons & Patient Assistance Programs". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 19 March 2016. Retrieved 10 November 2021.
↑ Surratt, H.; Kurtz, S.; Cicero, T.; Dart, R.; Baker, G.; Vorsanger, G. (April 2013). "Street prices of prescription opioids diverted to the illicit market: data from a national surveillance program". The Journal of Pain. 14 (4): S40. doi:10.1016/j.jpain.2013.01.455.

[AHFS2021-1] ୧.୦ ^୧.୧ ^୧.୨ ^୧.୩ ^୧.୪ ^୧.୫ ^୧.୬ ^୧.୭ "OxyMORphone Monograph for Professionals". Drugs.com. Archived from the original on 4 March 2021. Retrieved 10 November 2021.

[2] Sloan P (August 2008). "Review of oral oxymorphone in the management of pain". Therapeutics and Clinical Risk Management. 4 (4): 777–87. doi:10.2147/tcrm.s1784. PMC 2621383. PMID 19209260.{{cite journal}}: CS1 maint: unflagged free DOI (link)

[3] Sinatra, Raymond S.; Jahr, Jonathan S.; Watkins-Pitchford, J. Michael (14 October 2010). The Essence of Analgesia and Analgesics (in ଇଂରାଜୀ). Cambridge University Press. p. 123. ISBN 978-1-139-49198-3. Archived from the original on 10 November 2021. Retrieved 10 November 2021.

[Fis2006-4] Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery (in ଇଂରାଜୀ). John Wiley & Sons. p. 52X. ISBN 9783527607495. Archived from the original on 2021-10-25. Retrieved 2021-10-21.

[5] "Oxymorphone Prices, Coupons & Patient Assistance Programs". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 19 March 2016. Retrieved 10 November 2021.

[6] Surratt, H.; Kurtz, S.; Cicero, T.; Dart, R.; Baker, G.; Vorsanger, G. (April 2013). "Street prices of prescription opioids diverted to the illicit market: data from a national surveillance program". The Journal of Pain. 14 (4): S40. doi:10.1016/j.jpain.2013.01.455.

[୧]

[୨]

[୩]

[୪]

[୫]

[୬]